The benefit of the PARP inhibitor in patients with germline BRCA pathogenic variants remains evident 10 years after the first ...

Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to ...

AstraZeneca and MSD's PARP inhibitor Lynparza has improved long-term survival when given as adjuvant therapy for early breast ...

AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results ...

Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median ...

Lynparza demonstrates sustained survival benefits in Phase III OlympiA breast cancer trial, reducing death risk by 28% over ...

AstraZeneca & Merck announce OlympiA phase 3 trial of Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cancer: Rahway, New Jersey Friday, Dec ...

"KEYLYNK-001 is the first positive phase 3 trial for Keytruda plus Lynparza, highlighting our commitment to research that may ...

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative ...

Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median ...

RAHWAY, N.J., December 11, 2024--(BUSINESS WIRE)--AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United ...

Updated results from the OlympiA Phase III trial showed AstraZeneca and Merck & Co., Inc’s, known as MSD outside of the US and Canada, LYNPARZA® (olaparib) demonstrated sustained, clinically ...